

13. The method according to claim 11, wherein the heterologous gene is a secretable protein.

14. The method according to claim 13 wherein the protein is selected from a group consisting of Factor IX, ApoE,  $\beta$ -interferon, insulin, erythropoietin, growth hormone, and parathyroid hormone.

15. The method according to claim 11, wherein the heterologous gene is a dystrophin gene.

#### REMARKS

Claims 3 - 15 are pending. Claims 1 and 2 have been cancelled and rewritten as added claims 11 and 12, respectively. Claims 13-15 have also been added. Claims 3 - 6 have been rewritten as method claims. The amendments to claims 3 - 6 are supported by original claims 3 - 6. Added claims 11 to 15 are supported by original claims 1 to 4 and 6, respectively. This amendment contains no new matter.

The abstract of the disclosure is essentially identical to the abstract on the cover page of the published PCT application, of which this is a 371 application. This language is supported in the specification from page 3, line 2 to line 32.

This amendment is further supported throughout the specification. No new matter is added by this amendment.

No fees are believed due with this filing. However, the Assistant Commissioner for Patents is hereby authorized to charge any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account No. 08-3040.

Respectfully submitted,  
HOWSON AND HOWSON  
Attorneys for Applicants

By Cathy A. Kodroff  
Cathy A. Kodroff  
Registration No. 33,980  
Spring House Corporate Center  
Box 457  
Spring House, PA 19477  
Telephone (215) 540-9210  
Telefacsimile (215) 540-5818

CAK/kbk